瑞华泰(688323) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥79,256,915.65, representing a 44.88% increase compared to ¥54,703,500.18 in the same period last year[4] - The net profit attributable to shareholders was -¥18,414,939.50, a slight increase in loss from -¥16,574,890.90 year-on-year[4] - The increase in operating revenue was primarily driven by the capacity release of the Jiaxing project, leading to higher sales volume[8] - Total revenue for Q1 2025 reached ¥79,256,915.65, a 44.8% increase from ¥54,703,500.18 in Q1 2024[18] - Net loss for Q1 2025 was ¥18,414,939.50, compared to a net loss of ¥16,574,890.90 in Q1 2024, indicating a decline in performance[20] - Operating profit for Q1 2025 was -¥17,918,872.94, slightly worse than -¥16,317,966.73 in Q1 2024[19] Cash Flow and Liquidity - The net cash flow from operating activities was ¥34,214,425.62, showing a 3.99% increase from ¥32,902,787.08 in the previous year[4] - Cash received from sales in Q1 2025 was ¥67,243,064.37, down 20.4% from ¥84,275,755.31 in Q1 2024[22] - The cash inflow from operating activities was $96,855,662.89, compared to $102,849,413.68, showing a decrease of about 6%[23] - Cash and cash equivalents decreased to RMB 141,328,906.84 from RMB 152,211,590.34, indicating a decline of about 7.5%[15] - Cash and cash equivalents at the end of the period totaled $141,328,906.84, down from $94,141,640.85, representing an increase of about 50%[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,566,631,061.12, a slight increase of 0.10% from ¥2,563,947,151.17 at the end of the previous year[5] - Total liabilities amounted to ¥1,641,924,855.70, compared to ¥1,620,826,006.25 in the previous period[17] - Non-current liabilities decreased to ¥1,042,230,082.70 from ¥1,135,110,825.51[17] - The company's equity attributable to shareholders was ¥924,706,205.42, down from ¥943,121,144.92[17] Research and Development - Research and development expenses totaled ¥7,467,497.03, which is a 7.33% decrease from ¥8,058,136.82 in the same period last year[4] - The ratio of R&D expenses to operating revenue decreased to 9.42%, down 5.31 percentage points from 14.73% year-on-year[5] - Research and development expenses for Q1 2025 were ¥7,467,497.03, a decrease from ¥8,058,136.82 in Q1 2024[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,535[10] - The company has not reported any significant changes in shareholder relationships or actions during the reporting period[12] - There were no significant changes in the top 10 shareholders or their participation in margin trading and securities lending activities[12] Other Financial Information - The company recognized government subsidies amounting to ¥1,088,065.33, which are closely related to its normal operations[6] - The financial statements for the quarter ended March 31, 2025, are unaudited[13] - The company has not identified any other important information regarding its operational performance during the reporting period[13] Operating Costs - Total operating costs for Q1 2025 were ¥98,661,338.20, up 37.4% from ¥71,851,557.80 in Q1 2024[18]